Synthesis and evaluation of novel potent HCV NS5A inhibitors
Authors:
- 1 July 2012
- journal article
- research article
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 22 (14) , 4864-4868
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- New Merck and Vertex drugs raise standard of care in hepatitis CNature Biotechnology, 2011
- Advances in nucleoside monophosphate prodrugs as anti-HCV agentsAntiviral Therapy, 2010
- Resistance Analysis of the Hepatitis C Virus NS5A Inhibitor BMS-790052 in an In Vitro Replicon SystemAntimicrobial Agents and Chemotherapy, 2010
- Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effectNature, 2010
- Copper-catalyzed azide–alkyne cycloaddition (CuAAC) and beyond: new reactivity of copper(i) acetylidesChemical Society Reviews, 2010
- HCV drug discovery aimed at viral eradicationJournal of Viral Hepatitis, 2010
- Mono- and disalicylic acid derivatives: PTP1B inhibitors as potential anti-obesity drugsBioorganic & Medicinal Chemistry, 2007
- Ser2194 Is a Highly Conserved Major Phosphorylation Site of the Hepatitis C Virus Nonstructural Protein NS5AVirology, 2000
- Hepatitis C Virus NS5A Protein Is Phosphorylated by Casein Kinase IIBiochemical and Biophysical Research Communications, 1999
- Conformationally restricted arginine analogsThe Journal of Organic Chemistry, 1991